Get started
Aligos Therapeutics, Inc.Aligos Therapeutics, Inc.Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ALGS chart


Full chart

ALGS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪66.81 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−13.35 USD
Net income (FY)
‪−87.68 M‬ USD
Revenue (FY)
‪15.53 M‬ USD
Shares float
‪2.25 M‬
Beta (1Y)
1.39

Employees


Employees (FY)
66
Change (1Y)
−17 −20.48%
Revenue / Employee (1Y)
‪235.29 K‬ USD
Net income / Employee (1Y)
‪−1.33 M‬ USD

About Aligos Therapeutics, Inc.


Sector
Health Technology
CEO
Lawrence M. Blatt
Headquarters
South San Francisco
Website
aligos.com
Founded
2018
FIGI
BBG00QX7QH68
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is engaged in in developing therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

ALGS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of ALGS is 10.19 USD — it has increased by 2.72% in the past 24 hours. Watch Aligos Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Aligos Therapeutics, Inc. stocks are traded under the ticker ALGS.
ALGS stock has risen by 3.87% compared to the previous week, the month change is a 41.14% rise, over the last year Aligos Therapeutics, Inc. has showed a −45.65% decrease.
We've gathered analysts' opinions on Aligos Therapeutics, Inc. future price: according to them, ALGS price has a max estimate of 175.00 USD and a min estimate of 60.00 USD. Watch ALGS chart and read a more detailed Aligos Therapeutics, Inc. stock forecast: see what analysts think of Aligos Therapeutics, Inc. and suggest that you do with its stocks.
ALGS reached its all-time high on Jan 20, 2021 with the price of 937.75 USD, and its all-time low was 6.76 USD and was reached on Oct 8, 2024. View more price dynamics on ALGS chart.
See other stocks reaching their highest and lowest prices.
ALGS stock is 7.54% volatile and has beta coefficient of 1.39. Track Aligos Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Aligos Therapeutics, Inc. there?
Today Aligos Therapeutics, Inc. has the market capitalization of ‪32.57 M‬, it has increased by 8.19% over the last week.
Yes, you can track Aligos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Aligos Therapeutics, Inc. is going to release the next earnings report on Mar 6, 2025. Keep track of upcoming events with our Earnings Calendar.
ALGS earnings for the last quarter are −3.07 USD per share, whereas the estimation was −2.16 USD resulting in a −42.35% surprise. The estimated earnings for the next quarter are −2.50 USD per share. See more details about Aligos Therapeutics, Inc. earnings.
Aligos Therapeutics, Inc. revenue for the last quarter amounts to ‪1.27 M‬ USD, despite the estimated figure of ‪333.33 K‬ USD. In the next quarter, revenue is expected to reach ‪433.33 K‬ USD.
ALGS net income for the last quarter is ‪−19.26 M‬ USD, while the quarter before that showed ‪5.06 M‬ USD of net income which accounts for −480.54% change. Track more Aligos Therapeutics, Inc. financial stats to get the full picture.
No, ALGS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 66.00 employees. See our rating of the largest employees — is Aligos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Aligos Therapeutics, Inc. EBITDA is ‪−91.86 M‬ USD, and current EBITDA margin is −543.23%. See more stats in Aligos Therapeutics, Inc. financial statements.
Like other stocks, ALGS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Aligos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Aligos Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Aligos Therapeutics, Inc. stock shows the sell signal. See more of Aligos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.